B-Cell Immune Checkpoints Come of Age in Cardio-oncology

Circ Res. 2024 Mar;134(5):569-571. doi: 10.1161/CIRCRESAHA.124.324243. Epub 2024 Feb 29.

Authors

Alan Gutierrez^{1

2}, Javid J Moslehi¹

Affiliations

¹ Section of Cardio-Oncology and Immunology, Cardiovascular Research Institute (CVRI), University of California San Francisco, School of Medicine (A.G., J.M.).
² Yale University School of Medicine, New Haven, CT (A.G.).

PMID: 38422182
PMCID: PMC11141201 (available on 2025-03-01)
DOI: 10.1161/CIRCRESAHA.124.324243

No abstract available

Keywords: B-cells; Editorials; cardio-oncology; cardiotoxicity; doxorubicin; exercise; immunity, innate.

Publication types

Editorial
Comment

MeSH terms

Cardio-Oncology
Cardiotoxicity*
Doxorubicin / adverse effects
Heart Diseases* / chemically induced
Humans

Substances

Doxorubicin

Grants and funding